Assignee
VALNEVA AUSTRIA GMBH
AT·33 granted patents·15 pending applications·128 citations·filing 2013–2025
Top patents by PatentIndex Score
48 records- 0196US11572392B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2020·Granted Feb 7, 2023·6 cites·23 claims
- 0296US11524064B2Zika virus purificationVALNEVA AUSTRIA GMBH·Filed 2020·Granted Dec 13, 2022·7 cites·18 claims
- 0396US11219681B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2020·Granted Jan 11, 2022·9 cites·26 claims
- 0495US10744194B2Zika virus purificationVALNEVA AUSTRIA GMBH·Filed 2016·Granted Aug 18, 2020·11 cites·20 claims
- 0595US10639365B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2016·Granted May 5, 2020·6 cites·20 claims
- 0694US10766931B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2018·Granted Sep 8, 2020·9 cites·19 claims
- 0794US10357557B2Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2017·Granted Jul 23, 2019·13 cites·15 claims
- 0893US11684669B2CpG-adjuvanted SARS-CoV-2 virus vaccineVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jun 27, 2023·6 cites·30 claims
- 0993US11208439B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2018·Granted Dec 28, 2021·6 cites·19 claims
- 1093US9975927B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2015·Granted May 22, 2018·13 cites·11 claims
- 1193US9926343B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2016·Granted Mar 27, 2018·10 cites·18 claims
- 1292US12195501B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jan 14, 2025·1 cites·23 claims
- 1392US2026070950A1Mutant fragments of ospa and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2025·Application pending·0 cites
- 1491US11466058B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2019·Granted Oct 11, 2022·4 cites·10 claims
- 1591US11331382B2Zika virus purificationVALNEVA AUSTRIA GMBH·Filed 2016·Granted May 17, 2022·4 cites·9 claims
- 1691US10544194B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2016·Granted Jan 28, 2020·8 cites·9 claims
- 1791US2025018023A1Zika Virus VaccineVALNEVA AUSTRIA GMBH·Filed 2024·Application pending·0 cites
- 1890US10821166B2Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2019·Granted Nov 3, 2020·3 cites·18 claims
- 1989US10668146B2Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2017·Granted Jun 2, 2020·3 cites·12 claims
- 2088US12102673B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2023·Granted Oct 1, 2024·0 cites·32 claims
- 2187US11951163B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2023·Granted Apr 9, 2024·0 cites·58 claims
- 2287US11478540B2Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2021·Granted Oct 25, 2022·1 cites·12 claims
- 2384US12018054B2Multivalent OspA polypeptides and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2018·Granted Jun 25, 2024·3 cites·20 claims
- 2484US2025360191A1Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2025·Application pending·0 cites
- 2583US12324831B2Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2022·Granted Jun 10, 2025·0 cites·19 claims
- 2683US11110170B2Aluminum compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2020·Granted Sep 7, 2021·1 cites·20 claims
- 2782US2023295245A1Mutant fragments of ospa and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2022·Application pending·0 cites
- 2881US12005111B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jun 11, 2024·0 cites·58 claims
- 2981US2023322869A1Mutant fragments of ospa and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2023·Application pending·0 cites
- 3080US9913898B2Aluminum compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2016·Granted Mar 13, 2018·2 cites·18 claims
- 3180US9884115B2Aluminum compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2015·Granted Feb 6, 2018·2 cites·14 claims
- 3278US12331084B2Multivalent OspA polypeptides and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2024·Granted Jun 17, 2025·0 cites·20 claims
- 3377US12527863B2Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jan 20, 2026·0 cites·18 claims
- 3473US11357844B2Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2020·Granted Jun 14, 2022·0 cites·20 claims
- 3565US9492537B2Methods and compositions involving immunostimulatory oligodeoxynucleotidesVALNEVA AUSTRIA GMBH·Filed 2014·Granted Nov 15, 2016·0 cites·4 claims
- 3665US2025213667A1Clostridium difficile vaccineVALNEVA AUSTRIA GMBH·Filed 2023·Application pending·0 cites
- 3763US2024026412A1Improved methods of producing a lipidated proteinVALNEVA AUSTRIA GMBH·Filed 2021·Application pending·0 cites
- 3863US2023398210A1Improvements in vaccine formulations for medical useVALNEVA AUSTRIA GMBH·Filed 2021·Application pending·0 cites
- 3962US2015232517A1MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETOVALNEVA AUSTRIA GMBH·Filed 2013·Application pending·0 cites
- 4062US2022298493A1Inactivation process for virusesVALNEVA AUSTRIA GMBH·Filed 2022·Application pending·0 cites
- 4160US8952135B2S. agalactiae antigens I and IIVALNEVA AUSTRIA GMBH·Filed 2013·Granted Feb 10, 2015·0 cites·11 claims
- 4260US2014212448A1Klebsiella antigensVALNEVA AUSTRIA GMBH·Filed 2013·Application pending·0 cites
- 4357US2015250865A1MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETOVALNEVA AUSTRIA GMBH·Filed 2015·Application pending·0 cites
- 4455US2015010595A1Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid moleculeVALNEVA AUSTRIA GMBH·Filed 2014·Application pending·0 cites
- 4554US2024293531A1Inactivated sars-cov-2 virus vaccineVALNEVA AUSTRIA GMBH·Filed 2021·Application pending·0 cites
- 4651US9248180B2IC31 nanoparticlesVALNEVA AUSTRIA GMBH·Filed 2014·Granted Feb 2, 2016·0 cites·17 claims
- 4749US2016362480A1Novel oprf/i fusion proteins, their preparation and useVALNEVA AUSTRIA GMBH·Filed 2016·Application pending·0 cites
- 4846US12514912B2Compositions comprising three OspA fusion proteins for medical useVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jan 6, 2026·0 cites·24 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →